Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dosing Initiated in Phase I/II Clinical Trial of APR-246 in Ovarian Cancer

Published: Thursday, April 17, 2014
Last Updated: Thursday, April 17, 2014
Bookmark and Share
Promising data from trial has been presented in Journal of Clinical Oncology.

Aprea AB has announced that dosing has begun in the Phase I/II proof-of-concept clinical trial of APR-246 in combination with chemotherapy in patients with relapsed platinum sensitive high grade serous ovarian cancer. Aprea is a Karolinska Development AB portfolio company.

Cancers develop and spread due to the malfunction of the cells’ normal growth control mechanisms. One of the best-known cancer genes is p53 that can trigger the cellular suicide program to eliminate cancer cells. In about half of all tumors, p53 is mutated and no longer functions normally. This allows cancer cell survival and rapid tumor growth.

Aprea has successfully developed substances that can restore normal function to the p53 protein and thereby induce efficient cancer cell death and overcome resistance to antitumoral therapy. To the company’s knowledge, APR-246 is the only compound with this mechanism of action in clinical development.

"Ovarian cancer has a poor prognosis, as the disease is often fairly advanced by the time these patients experience their first symptoms. Present therapies for recurrent ovarian cancer have little impact on survival, and we are eager to evaluate whether APR-246 can extend the efficacy of second line therapy", said John A Green, Principal Investigator of the clinical trial.

"The synergistic effects of APR-246 and carboplatin have resulted in very potent antitumor activity in preclinical models. We now look forward to evaluate the compound’s safety profile and clinical activity in combination treatment of ovarian cancer patients", said Ulf Björklund, CEO at Aprea.

APR-246 has previously been tested in a clinical Phase I/II trial in 32 patients with refractory hematological malignancies or prostate carcinoma.

“We are excited about this trial and will follow it with great interest. About 60% of all ovarian cancer patients have mutated p53 and ovarian cancer patients with p53 mutations are less responsive to platinum than patients with wild type p53. Thus, it is an indication where Aprea’s APR-246 could make a difference for these patients with a great need for better treatment”, said Torbjörn Bjerke, CEO of Karolinska Development.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aprea Presents Preliminary Clinical Phase Ib/II Results in Ovarian Cancer at AACR
Company presents results with APR-246 - a novel candidate drug that restores mutant p53 protein into its wild-type function.
Tuesday, April 21, 2015
Aprea Presents Preclinical Data at AACR
Data reveals that APR-246 resensitizes ovarian cancer cells to platinum compounds and doxorubicin.
Tuesday, April 08, 2014
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!